<DOC>
	<DOCNO>NCT01736878</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Sorafenib versus placebo subject locally advanced medullary thyroid cancer ( MTC ) . The primary study objective compare Progression-free Survival ( PFS ) Sorafenib treatment group placebo treatment group patient advance MTC .</brief_summary>
	<brief_title>Efficacy Safety Study Sorafenib Treat Advanced Medullary Thyroid Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Inpatient outpatient ≥ 18 year age Histologically confirm medullary thyroid carcinoma Recurrent persistent local disease and/or distant metastases No one prior line systemic therapy Best available supportive care control ( endocrine ) symptom At least one define lesion CT MRI evaluable Response Evaluation Criteria Solid Tumors ( RECIST v1.1 ) , least one define lesion CT MRI evaluable RECIST combination elevate tumour marker Progression within previous 12 month Hb &gt; 8g/dl , white blood cell ( WBC ) &gt; 3.000 cells/mm³ ( ANC &gt; 1.500 cells/mm³ ) , platelets &gt; 100.000 cells/mm³ , bilirubin &lt; 2mg/dl , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x upper limit normal ( ULN ) Performance status : WHO ≤ 2 ; Karnofsky index ≥ 50 % Sufficient renal function ( creatinin &lt; 1.5 mg/dl creatinin clearance &gt; 30ml/min ) International normalize ratio ( INR ) partial thromboplastin time ( PTT ) &lt; 1.5 x ULN No acute infection Staging study ( MRT CT Calcitonin CEA ) complete within four week protocol randomisation Women childbearing potential negative serum pregnancy test Women men childbearing potential use adequate contraception Signed date write informed consent Unresolved toxicity ( i.e . neurotoxicity ) attribute prior therapy high National Cancer InstituteCommon Toxicity Criteria Adverse Effects ( NCICTCAE version 4 ) Grade 2 ( exclude case alopecia ) Patients history allergic hypersensitivity reaction study drug placebo excipients Current participation another investigational trial Patients significant cardiovascular disease Cardiac ventricular arrhythmia require antiarrhythmic therapy betablockers digoxin Congenital long correct QT interval ( QTc ) syndrome , history drug induce QTc prolongation , QTc interval unmeasurable 450 m Abnormal serum electrolytes potassium , magnesium calcium Uncontrolled hypertension , despite optimal management Major surgery , open biopsy , significant traumatic injury within 30 day prior randomization Nonhealing wound , ulcer , bone fracture Evidence history bleed diathesis coagulopathy disorder Hemorrhage/bleeding event ≥ Grade 3 Thrombotic embolic event include transient ischemic attack within past 6 month Subjects symptomatic brain metastasis Subjects brain metastasis corticosteroid treatment Pregnant breastfeeding patient Patients uncontrolled infection Known HIV infection infection hepatitis B C Immunosuppression Subjects seizure disorder require medication • Subjects undergoing renal dialysis Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result Any malabsorption condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Medullary Thyroid Carcinoma</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Efficacy</keyword>
</DOC>